GlassScriptPhysician profile
Hideki Shikata
NPI 1578590816
$10,488.36
in general payments reported to CMS, 2019-2025
32 companies · $2,519 in 2025
The $2,519 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $474 · 2021: $919 · 2022: $1,782 · 2023: $1,642 · 2024: $2,111 · 2025: $2,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,271.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,694.24 | 2019-2025 | Jardiance |
| Amgen INC. | $2,046.30 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,212.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $647.77 | 2019-2022 | |
| Novo Nordisk INC | $620.32 | 2021-2025 | Ozempic |
| Lilly USA, LLC | $462.56 | 2019-2025 | Jardiance, Mounjaro |
| Horizon Therapeutics Plc | $391.75 | 2023 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $299.14 | 2024-2025 | Voquezna |
| Abbott Laboratories | $242.95 | 2022-2024 | Freestyle Libre 3, Eterna |
| Otsuka America Pharmaceutical, INC. | $239.31 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $216.13 | 2021-2025 | |
| Glaxosmithkline, LLC. | $168.02 | 2019-2024 | Arexvy, Shingrix, Pediarix |
| Axsome Therapeutics, INC. | $147.74 | 2025 | Symbravo |
| Idorsia Pharmaceuticals US INC | $121.82 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.15 | 2024-2025 | Xifaxan, Trulance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $111.28 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $110.94 | 2023 | Strensiq |
| Sanofi-Aventis U.S. LLC | $106.48 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $105.60 | 2024 | Inpefa |
| Astellas Pharma US INC | $72.21 | 2023 | Veozah |
| Exact Sciences Corporation | $54.71 | 2023-2024 | Cologuard Collection Kit |
| Cranial Technologies, INC | $53.87 | 2022-2023 | Doc Band |
| Pfizer INC. | $53.72 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $35.37 | 2019 | |
| Merck Sharp & Dohme LLC | $28.60 | 2019-2022 | |
| Genentech USA, INC. | $20.72 | 2020 | |
| Abbvie INC. | $20.50 | 2021 | |
| Allergan, INC. | $18.61 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.33 | 2022 | |
| Lundbeck LLC | $16.54 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $16.53 | 2022 | |
| Zyla Life Sciences, INC. | $15.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hideki Shikata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.